AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.

about

AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.

Item

http://www.wikidata.org/entity/Q54333318

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@en

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@nl

type

Item

label

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@en

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@nl

prefLabel

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@en

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@nl

P1476

AHI1 gene expression levels an ...... nic myeloid leukemia patients.

@en

P2093

Feride Iffet Sahin

http://www.w3.org/2001/XMLSchema#string

Hakan Ozdogu

http://www.w3.org/2001/XMLSchema#string

Sema Karakus

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Molecular mechanisms of transformation by the BCR-ABL oncogene.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

BCR-ABL in chronic myelogenous leukemia--how does it work?

Milestones and monitoring in patients with CML treated with imatinib.

P304

357-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1179/102453311X13127324303272

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tuğçe Bulakbaşı Balcı

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22183070

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia